The Omnipod DASH™ Insulin Management System (Insulet Corp, Billerica, MA) is a discreet, tubeless, wearable insulin pump that holds up to 200 units of U-100 insulin and delivers therapy through customizable basal rates and bolus amounts. This recently FDA-cleared system consists of the insulin pump ("Pod"), which is worn on body and delivers insulin, and the Personal Diabetes Manager (PDM), which is a handheld device used to wirelessly control and monitor the Pod functionality. The PDM can also be paired with the CONTOUR NEXT ONE blood glucose (BG) meter (Ascensia Diabetes Care, Basel, Switzerland) to wirelessly receive BG readings. This review provides a detailed description of the Pod and PDM. Key features of the Pod are described, including the novel pump delivery mechanism, waterproof (IP28) housing design, and automated cannula insertion. The technology introduced in the new system, such as touchscreen PDM interface, Bluetooth wireless technology, and wireless internet connectivity, is also presented. Last, Omnipod Insulin Management System clinical data are reviewed, including early feasibility results for the Omnipod Horizon™ Automated Glucose Control hybrid closed-loop system.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313290 | PMC |
| http://dx.doi.org/10.1177/1932296818798836 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced Metabolic Control in a Pediatric Population with Type 1 Diabetes Mellitus Using Hybrid Closed-Loop and Predictive Low-Glucose Suspend Insulin Pump Treatments.
Pediatr Rep
December 2024
Department of Endocrinology, Diabetes Mellitus, Nutrition and Metabolic Disorders, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Background: Insulin pumps coupled with continuous glucose monitoring sensors use algorithms to analyze real-time blood glucose levels. This allows for the suspension of insulin administration before hypoglycemic thresholds are reached or for adaptive tuning in hybrid closed-loop systems. This longitudinal retrospective study aims to analyze real-world glycemic outcomes in a pediatric population transitioning to such devices.
View Article and Find Full Text PDFExperience of People with Diabetes Treated with Insulin Delivery Systems in France: A Comparative Analysis of Multiple Daily Injections, Tubeless Pumps, Tubed Pumps, and Hybrid Closed Loops.
Diabetes Ther
December 2024
IMMEDIAB Laboratory, Institut Necker Enfants Malades, INSERM U1151, CNRS, UMR 8253, Paris, France.
Introduction: While people with diabetes (PWD)'s experiences with their insulin delivery systems (IDS) are frequently reported in clinical trials, few real-world data exist on the subject. This study aimed to assess the real-world experience and satisfaction with IDS in PWD.
Methods: This cross-sectional survey of PWD treated with tubed or tubeless insulin pumps, hybrid closed loop (HCL) systems, or multiple daily injections (MDI) for at least 3 months ran from 4 to 16 May 2023.
Applying auricular magnetic therapy to decrease blood glucose levels and promote the healing of gangrene in diabetes patients: a case report.
J Med Case Rep
December 2024
Beijing Acupuncture and Chinese Herbology, 19 Edgemoor Road, Lutherville-Timonium, MD, 21093, USA.
Background: Magnetic therapy has demonstrated beneficial effects for reducing pain, nausea, neuropathy, and various other health concerns in the human body. To our knowledge, limited research has documented the use of auricular static magnetic therapy as a potential treatment for diabetes. This report presents the first evidence of using magnetic discs placed at acupuncture points on the human ear to decrease blood glucose levels and promote the healing of gangrene in diabetic patients.
View Article and Find Full Text PDFBackground: Older adults with type 1 diabetes are at risk for serious hypoglycemia. Automated insulin delivery can reduce risk but has not been sufficiently evaluated in this population.
Methods: We conducted a multicenter, randomized crossover trial in adults older than or equal to 65 years of age with type 1 diabetes.
Addressing Disparities Using Continuous Glucose Monitors and Remote Patient Monitoring for Youth With Type 1 Diabetes.
J Diabetes Sci Technol
December 2024
Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University, Stanford, CA, USA.
Background: Youth with type 1 diabetes (T1D) and public insurance have lower diabetes technology use. This pilot study assessed the feasibility of a program to support continuous glucose monitor (CGM) use with remote patient monitoring (RPM) to improve glycemia for youth with established T1D and public insurance.
Methods: From August 2020 to June 2023, we provided CGM with RPM support via patient portal messaging for youth with established T1D on public insurance with challenges obtaining consistent CGM supplies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!